Protara Therapeutics, Inc. (TARA) Balance Sheet

The equity expansion appears to be externally financed, since the accumulated deficit grew by roughly $130M while total assets moved in step with cash inflows. This pattern suggests the balance sheet is strengthening on paper only through issuance, not through operating progress. Investors should monitor whether future equity raises continue to offset the widening deficit.

The current ratio of 10.97 reflects a small liability base of $14.8M against assets dominated by cash and other short-term holdings, which suggests near-term obligations are not the binding constraint. However, the sharp cash decline against quarterly operating losses of roughly $21M to $23M implies a runway measured in quarters rather than years. The data does not disclose financing commitments, so the runway depends on access to future capital.

The debt figure is small relative to equity and assets, so refinancing risk appears limited based on reported figures. Low leverage means the company's solvency is governed by equity funding rather than debt service. The more relevant constraint is operating burn, not borrowing capacity.

The low PPE balance is consistent with an outsourced development model and minimal capital intensity. The disappearance of goodwill between quarters warrants further investigation, as the data does not explain whether it was impaired, reclassified, or derecognized. Asset quality therefore rests mainly on the cash balance rather than productive fixed assets.